معرفی
David Kerr is a Professor of Cancer Medicine and Consultant Physician at the University of Oxford, affiliated with the Nuffield Division of Clinical Laboratory Sciences. He leads the Kerr and Pezzella Group, focusing on colorectal cancer clinical trials and the molecular mechanisms underlying tumor growth, particularly the non-angiogenic pathway. His research integrates biomarker development, anti-angiogenic therapies, and genomic analysis to improve patient outcomes. Key collaborations include work with Dr. Rachel Midgley on adjuvant chemotherapy trials (e.g., QUASAR 2) and partnerships with institutions like AstraZeneca. His group has pioneered prognostic mRNA signatures and biomarkers for therapies like bevacizumab.
Research interests span colorectal cancer genetics, immunotherapy resistance, and precision medicine. Notable achievements include identifying cancer susceptibility SNPs and advancing understanding of tumor vasculature dynamics. Awards include CBE, FMedSci, and FRCP. Funding comes from governments (e.g., Malaysia, Saudi Arabia) and industry. He also co-leads the Kerr-Cai Group exploring epigenetic regulation in cholangiocarcinoma.
Recent work emphasizes AI-driven diagnostic tools for histopathology and ctDNA-based recurrence prediction (CORRECT-MRD I). His lab’s focus on multi-omic analyses and clinical translation aims to bridge basic science and patient care, addressing global cancer disparities through initiatives like the Africa-Oxford-Harvard/Hopkins consortium.
